Afmedicinering i danske kliniske behandlingsvejledninger

Translated title of the contribution: Deprescribing in Danish clinical treatment guidelines

Carina Lundby, Alaa Hassan Burghle, Jesper Ryg, Larsa Abuna, Walaa Abdulmanem Alnabhan, Jinthusaa Kumaran Thanikaikumaran, Arin Esmael, Jens Søndergaard, A Pottegård

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Lack of clinical guidance constitutes a significant barrier to deprescribing. Within Danish clinical guidelines on treatment of dementia, type 2 diabetes, hypertension, and osteoporosis, only limited attention was given to deprescribing. For dementia, type 2 diabetes, and osteoporosis, guidance was primarily focused on when to consider and implement deprescribing, with limited practical guidance on how to deprescribe. No guidance for deprescribing antihypertensives was identified. This highlights a need to consider deprescribing more broadly when developing and updating clinical guidelines, as argued in this review.
Translated title of the contributionDeprescribing in Danish clinical treatment guidelines
Original languageDanish
Article numberV01220063
JournalUgeskrift for Laeger
ISSN0041-5782
Publication statusE-pub ahead of print - 4. Jul 2022

Fingerprint

Dive into the research topics of 'Deprescribing in Danish clinical treatment guidelines'. Together they form a unique fingerprint.

Cite this